CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating...
Year: 2025
Safety Shot to Acquire Yerbaé Brands Corp., adding approximately $12 Million to Annual Revenue and Creating a Potential Force in Wellness and Functional Beverages
Yerbaé is a scalable, growth-oriented complementary brand with a large and growing addressable marketYerbaé creates clean, simple, and delicious plant-based...
Vericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025
CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine...
Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical Trial
SARASOTA, FL, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage...
SELLAS Announces Key Business Objectives for 2025
- Independent Data Monitoring Committee to Perform Interim Analysis of Phase 3 REGAL Study in January 2025 - - SLS009:...
Now Open: VITAS® Healthcare Inpatient Hospice Unit in Fort Worth
Freestanding homelike facility for specialized end-of-life care will serve 500+ patients annuallyFORT WORTH, Texas, Jan. 08, 2025 (GLOBE NEWSWIRE) --...
Kailera Therapeutics Appoints Laurie Stelzer as Chief Financial Officer
Industry executive with more than 25 years of finance and strategic leadership experienceBOSTON and SAN DIEGO, Jan. 08, 2025 (GLOBE...
60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis
Case reports published in medical literature suggest that tafenoquine combined with standard-of-care treatment exhibits a high cure rate in immunosuppressed...
Araris Biotech AG Announces Research Collaboration and Option to License Agreement with Chugai Pharmaceutical Co. to Develop Next-Generation ADCs Using Araris’ AraLinQ™ technology
Araris will use proprietary AraLinQ™ linker-conjugation platform to generate novel ADCs using antibodies against targets provided by ChugaiAraris to receive...
Indaptus Therapeutics Provides Year-End Review and Outlook for 2025
Continued Strong Clinical Progress and Planned New Combination Trial Provide Significant Momentum for 2025NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE)...
Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and...
Collegium Provides 2025 Financial Guidance and Business Update
– Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM® Net Revenue...
Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass. and BOULDER, Colo., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on...
Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline
All-Stock Acquisition Strategy Targets Multiple Small Companies with FDA-Approved Products to Drive Growth and Shareholder ValueWARRINGTON, Pa., Jan. 08, 2025...
Microbot Medical Announces $8.6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
HINGHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into...
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
Denali expects to submit a Biologics License Application for tividenofusp alfa in early 2025 for regulatory review under the accelerated...
Noema Pharma Appoints Michael Samar as Chief Financial Officer
Appointment Further Strengthens Leadership Team; Follows Appointment of Volker Knappertz, M.D., as Executive Vice President of Research & DevelopmentBASEL, Switzerland,...
Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections
Data show favorable safety and tolerability with dosing up to 800 mg for 10 daysPlans to initiate human challenge study...
Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025
NORWOOD, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced...
Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate
Top-line Phase 2/3 data readout for CTX-009, now named tovecimig (a DLL4 x VEGF-A bispecific), in patients with biliary tract...